Saatja: CHULKOVA, Elena <
[email protected]>
Saadetud: 14.10.2020 12:18
Teema: Consultation on the Global Leprosy Strategy, 2021-2030
Ñîîáùåíèå íà ðóññêîì ÿçûêå ñìîòðèòå íèæå
The message in Russian follows below
Sent on behalf of Dr Nino Berdzuli, Director, Division of Country Health
Programs
Dear National Counterparts,
Consultation on the Global Leprosy Strategy, 2021-2030
I am pleased to inform you that the Global Leprosy Programme of the World
Health Organization in collaboration with WHO Regional Offices is
planning to conduct on 2629 October 2020 a virtual global consultation
devoted to new strategy on control and elimination of leprosy for the
years 2021-2030.
The main objective of the consultation is to present the draft Global
Leprosy Strategy 20212030 and discuss its elements, including procedures
for verification of interruption of leprosy transmission, as well as
share experiences of countries on implementation of different components
of the leprosy control and elimination programmes. The meeting will be
conducted in English and translation into Russian, French, Spanish and
Portuguese will be provided.
Preliminary agenda of the consultation and draft Global Leprosy Strategy
20212030 are attached for your information.
I have pleasure in inviting you to nominate leading specialists in the
area of control and prevention of leprosy from your country to
participate at the consultation. We look forward to receiving your
nominations, giving the name, functional title and address of the
proposed participants at your early convenience and not later than 20
October 2020.
Nominated specialists are invited to register using the following link:
On all issues related to this consultation, please contact Dr Elkhan
Gasimov (), Technical Officer on malaria, neglected tropical diseases and
other vector-borne diseases.
Yours sincerely,
Dr Nino Berdzuli,
Director,
Division of Country Health Programme
_____________________________________________
Ñîîáùåíèå îòïðàâëåíî îò èìåíè ä-ða Nino Berdzuli, Äèðåêòîðà îòäåëà
ñòðàíîâûõ ïðîãðàìì çäðàâîîõðàíåíèÿ
Óâàæàåìûå íàöèîíàëüíûå êîîðäèíàòîðû,
Êîíñóëüòàöèÿ, ïîñâÿùåííàÿ íîâîé Ãëîáàëüíîé Ñòðàòåãèè ïî Ëåïðå íà 2021-
2030 ãã.
Èìåþ ÷åñòü ïðîèíôîðìèðîâàòü Âàñ î òîì, ÷òî Ãëîáàëüíàÿ Ïðîãðàììà ïî Ëåïðå
Âñåìèðíîé îðãàíèçàöèè çäðàâîîõðàíåíèÿ, ñîâìåñòíî ñ Ðåãèîíàëüíûìè áþðî ÂÎÇ
ïëàíèðóåò ïðîâåäåíèå 2629 îêòÿáðÿ 2020 ãîäà âèðòóàëüíîé ãëîáàëüíîé
êîíñóëüòàöèè, ïîñâÿùåííîé íîâîé ñòðàòåãèè ïî áîðüáå è ýëèìèíàöèè ëåïðû íà
2021-2030 ãîäû.
Îñíîâíîé öåëüþ êîíñóëüòàöèè ÿâëÿåòñÿ ïðåçåíòàöèÿ ïðîåêòà íîâîé Ãëîáàëüíîé
Ñòðàòåãèè ïî Ëåïðå íà 20212030 ãîäû è îáñóæäåíèÿ ðàçíûõ åå ýëåìåíòîâ,
âêëþ÷àÿ ïðîöåäóðû âåðèôèêàöèè ïåðåðûâà ïåðåäà÷è ëåïðû, à òàêæå îáìåí
îïûòîì ìåæäó ñòðàíàìè ïî âíåäðåíèþ ðàçíûõ êîìïîíåíòîâ ïðîãðàìì ïî áîðüáå
è ýëèìèíàöèè ëåïðû. Ðàáî÷èì ÿçûêîì êîíñóëüòàöèè ÿâëÿåòñÿ àíãëèéñêèé, ñ
îáåñïå÷åíèåì ïåðåâîäà íà ðóññêèé, ôðàíöóçñêèé, èñïàíñêèé è ïîðòóãàëüñêèé
ÿçûêè.
Ïðåäâàðèòåëüíàÿ ïðîãðàììà êîíñóëüòàöèè è ïðîåêò Ãëîáàëüíîé Ñòðàòåãèè ïî
Ëåïðå íà 20212030 ãîäû (îáà äîêóìåíòà íà àíãëèéñêîì ÿçûêå) ïðèëîæåíû ê
äàííîìó ñîîáùåíèþ äëÿ Âàøåé èíôîðìàöèè.
ß èìåþ ÷åñòü ïðåäëîæèòü Âàì íàçíà÷èòü äëÿ ó÷àñòèÿ â ðàáîòå êîíñóëüòàöèè
âåäóùèõ ñïåöèàëèñòîâ â îáëàñòè áîðüáû è ïðîôèëàêòèêè ëåïðû èç Âàøåé
ñòðàíå. Ìû íàäååìñÿ ïîëó÷èòü îò Âàñ ñâåäåíèÿ î íàçíà÷åííûõ Âàìè
ó÷àñòíèêàõ, ñ óêàçàíèåì èìåíè, ôàìèëèè, äîëæíîñòè è àäðåñà êàæäîãî
ó÷àñòíèêà, ïî âîçìîæíîñòè â áëèæàéøåå âðåìÿ, íî íå ïîçäíåå 20 îêòÿáðÿ
2020 ãîäà.
Íàçíà÷åííûå ñïåöèàëèñòû äîëæíû çàðåãèñòðèðîâàòüñÿ ïî ñëåäóþùåé ññûëêå:
Ïo âñåì âîïðîñàì, ñâÿçàííûì ñ äàííîé êîíñóëüòàöèåé, ïðîñèì îáðàùàòüñÿ ê
ä-ðó Ýëüõàíó Ãàñûìîâó (), Òåõíè÷åñêîìó ñïåöèàëèñòó ïî ìàëÿðèè, çàáûòûì
òðîïè÷åñêèì áîëåçíÿì è äðóãèì ïàðàçèòàðíûì çàáîëåâàíèÿì.
Ñ óâàæåíèåì,
Ä-ð Nino Berdzuli,
Äèðåêòîð,
Îòäåë ñòðàíîâûõ ïðîãðàìì çäðàâîîõðàíåíèÿ
Global consultation with NLP managers, partners and affected persons on Global Leprosy Strategy 2021 ‒ 2030 Virtual meeting ‘West’ 26-29 Oct 2020, 18 :00- 20: 30 hrs ( IST ) – Africa, Europe, Americas Translation will be provided in English, French, Spanish , Portuguese and Russian Agenda Mexico Washington Brasilia Brazzaville Geneva Cairo Moscow Addis Abeba India Item 26 October 2020 Day 1 07:30-08:00 08:30-09:00 09:30-10:00 13:30-14:00 14:30-15:00 15:30-16:00 18:00-18:30 Inaugural session Inaugural address by RD SEARO Introduction of participant groups Objectives and expected outcomes Procedures 08:00-08:15 09:00-09:15 10:00-10:15 14:00-14:15 15:00-15:15 16:00-16:15 18:30-18:45 Global leprosy situation: current si tuation 08:15-08:45 09:15-09:45 10:15-10:45 14:15-14:45 15:15-15:45 16:15-16:45 18:45-19:15 Challenges in implementation : Ethiopia Brazil Somalia 08:45-08:50 09:45-09:50 10:45-10:50 14:45-14:50 15:45-15:50 16:45-16:50 19:15-19:20 Comfort break 08:50-09:20 09:50-10:20 10:50-11:20 14:50-15:20 15:50-16:20 16:50-17:20 19:20-19:50 Global Leprosy Strategy 2021‒2030 Development process Vision, mission, goal, targets, overview of pillars 09:20-09:40 10:20-10:40 11:20-11:40 15:20-15:40 16:20-16:40 17:20-17:40 19:50-20:10 Roadmap for NTDs, 2021‒2030 Global architecture for elimination of multiple diseases 09:40-10:00 10:40-11:00 11:40-12:00 15:40-16:00 16:40-17:00 17:40-18:00 20:10-20:30 Comments from TAG-Leprosy 27 October 2020 Day 2 07:30-07:45 08:30-08:45 09:30-09:45 13:30-13:45 14:30-14:45 15:30-15:45 18:00-18:15 Contact tracing and post-exposure prophylaxis: WHO guidance and next steps 07:45-08:15 08:45-09:15 09:45-10:15 13:45-14:15 14:45-15:15 15:45-16:15 18:15-18:45 Contact tracing and/or post-exposure prophylaxis: country perspectives: Tanzania Colombia Ghana 08:15-08:30 09:15-09:30 10:15-10:30 14:15-14:30 15:15-15:30 16:15-16:30 18:45-19:00 Contact tracing and/or post-exposure prophylaxis: perspective of persons affected by leprosy 08:30-08:45 09:30-09:45 10:30-10:45 14:30-14:45 15:30-15:45 16:30-16:45 19:00-19:15 Contact tracing and/or post-exposure prophylaxis: perspective of partners 08:45-08:50 09:45-09:50 10:45-10:50 14:45-14:50 15:45-15:50 16:45-16:50 19:15-19:20 Comfort break 08:50-09:20 09:50-10:20 10:50-11:20 14:50-15:20 15:50-16:20 16:50-17:20 19:20-19:50 Disability care: country perspective Russia Paraguay 09:20-09:40 10:20-10:40 11:20-11:40 15:20-15:40 16:20-16:40 17:20-17:40 19:50-20:10 Disability care: perspective of persons affected by leprosy 09:40-10:00 10:40-11:00 11:40-12:00 15:40-16:00 16:40-17:00 17:40-18:00 20:10-20:30 Disability care: perspective from partners 28 Oct ober 2020 Day 3 07:30-07:50 08:30-08:50 09:30-09:50 13:30-13:50 14:30-14:50 15:30-15:50 18:00-18:20 Interruption of transmission, elimination of disease Report of Task force 07:50-08:10 08:50-09:10 09:50-10:10 13:50-14:10 14:50-15:10 15:50-16:10 18:20-18:40 Leprosy elimination: indicators to be monitored Roadmap indicators Post-elimination surveillance 08:10-08:40 09:10-09:40 10:10-10:40 14:10-14:40 15:10-15:40 16:10-16:40 18:40-19:10 Interruption of transmission, elimination of disease: country experiences Morocco Cuba 08:40-08:45 09:40-09:45 10:40-10:45 14:40-14:45 15:40-15:45 16:40-16:45 19:10-19:15 Comfort break 08:45-09:00 09:45-10:00 10:45-11:00 14:45-15:00 15:45-16:00 16:45-17:00 19:15-19:30 Country roadmaps for zero leprosy: introduction 09:00-09:30 10:00-10:30 11:00-11:30 15:00-15:30 16:00-16:30 17:00-17:30 19:30-20:00 Country roadmaps for zero leprosy: country perspectives: Mexico DR Congo 09:30-09:45 10:30-10:45 11:30-11:45 15:30-15:45 16:30-16:45 17:30-17:45 20:00-20:15 Country roadmaps for zero leprosy: perspective from partners 09:45-10:00 10:45-11:00 11:45-12:00 15:45-16:00 16:45-17:00 17:45-18:00 20:15-20:30 Country roadmaps for zero leprosy: comments by TAG members 29 Oct ober 2020 Day 4 07:30-08:00 08:30-09:00 09:30-10:00 13:30-14:00 14:30-15:00 15:30-16:00 18:00-18:30 Stigma and discrimination: country perspectives Senegal Brazil 08:00-08:10 09:00-09:10 10:00-10:10 14:00-14:10 15:00-15:10 16:00-16:10 18:30-18:40 Stigma and discrimination: viewpoint of UN Special Rapporteur 08:10-08:25 09:10-09:25 10:10-10:25 14:10-14:25 15:10-15:25 16:10-16:25 18:40-18:55 Stigma and discrimination: perspective of partners 08:25-08:40 09:25-09:40 10:25-10:40 14:25-14:40 15:25-15:40 16:25-16:40 18:55-19:10 Stigma and discrimination: perspective of persons affected by leprosy 08:40-09:00 09:40-10:00 10:40-11:00 14:40-15:00 15:40-16:00 16:40-17:00 19:10-19:30 Research 09:00-09:10 10:00-10:10 11:00-11:10 15:00-15:10 16:00-16:10 17:00-17:10 19:30-19:40 Comfort break 09:10-09:35 10:10-10:35 11:10-11:35 15:10-15:35 16:10-16:35 17:10-17:35 19:40-20:05 Statements by key partners WHO Goodwill Ambassador for Leprosy Elimination GPZL ILEP Novartis Affected persons 09:35-09:50 10:35-10:50 11:35-11:50 15:35-15:50 16:35-16:50 17:35-17:50 20:05-20:20 Conclusions and recommendations 09:50-10:00 10:50-11:00 11:50-12:00 15:50-16:00 16:50-17:00 17:50-18:00 20:20-20:30 Closing session
TOWARDS ZERO LEPROSY GLOBAL LEPROSY (HANSEN ’S DISEASE) STRATEGY 2021-2030 CONSULTATION DRAFT: SEPTEMBER 2020 ABBREVIATIONS ADR Adverse drug reactions NFI Nerve function impairment AMR Antimicrobial resistance NLP National leprosy programme C S O Civil society organisation NTD Neglected tropical disease CBR Community based rehabilitation SDG Sustainable development goal GPZL Global Partnership for Zero Leprosy TAG Technical Advisory Group ILEP International Federation of Anti-Leprosy Associations UHC Universal health coverage MDT Multi-drug therapy WHA World Health Assembly NGO Non-governmental organisation WHO World Health Organization DEVELOPMENT AND CONTRIBUTORS Nov 2019: Request for input on 2030 targets for 2021-2030 NTD Roadmap and Global Leprosy Strategy sent to WHO TAG -Leprosy and partners Jan 2019: Input from delegates at First International Dermacon , Bengaluru, India Feb 2019: Online survey of NLPs and other partners on possible 2030 targets conducted by GPZL over two iterations and results shared online Apr 2019: Update and notable developments shared during WHO NTD-STAG meeting Apr 2019: First draft strategy presented during ‘ Global training of NLP managers from priority leprosy-endemic countries ’ , Bangkok, Thailand . I nputs sought from NLPs present Apr-May 2019: Inputs sought on first draft strategy by email from technical experts in leprosy Jun 2019: Summary of d raft s trategy presented during International Leprosy Training Programme for Developing Countries, Tai’an , China . Input sought from delegates. Jul -Sep 2019: Process slowed pending consultation and completion of NTD Roadmap 2021-2030 . GPZL partners invited to comment on l epros y pages of NTD Roadmap . Leprosy pages finalised with partners during NNN Conference, Liverpool, England Nov 2019: Strategy outline discussed during ‘ Training of NLP managers from hyper-endemic countries ’ , Pohnpei, Federated States of Micronesia Nov 2019: Further i nputs received from WHO TAG-Leprosy Jan 2020: Overview presented at ‘ Informal consultation on defining criteria to declare elimination of transmission of leprosy ’ , Mexico City, Mexico Jun- Aug 2020: Detailed write-up of final draft ready for consultation Oct 2020: Global consultation [ MORE TO FOLLOW ] STRATEGY AT A GLANCE TOWARDS ZERO LEPROSY GLOBAL LEPROSY (HANSEN ’S DISEASE) STRATEGY 2021-2030 Long term vision Zero leprosy: zero infection and disease, zero disability, zero stigma and discrimination Goal Elimination of leprosy (interruption of transmission) Global targets for 2030 120 countries reporting zero new autochthonous cases 70 % reduction in annual number of new cases detected 90% reduction in rate per million of new cases with grade-2 disability 90% reduction in rate per million children of new child cases with leprosy Strategic pillars and key components 1: Implement integrated , country-owned zero leprosy roadmaps in all endemic countries Political commitment with adequate resources for leprosy in integrated context National partnerships for zero leprosy and zero leprosy roadmaps engaging all stakeholders Capacity building in the healthcare system for quality services Effective surveillance and improved data management systems Monitoring of antimicrobial resistance and adverse drug reactions 2: Scale up leprosy prevention alongside integrated active case detection Contact tracing for all new cases P reventive chemotherapy scaled up Integrated a ctive case-finding in targeted populations Existing and potential new v accines 3: Manage leprosy and its complications and prevent new disability Early case detection, accurate diagnosis and prompt treatment Access to comprehensive, well-organised referral facilities Diagnosis and management of leprosy reactions , neuritis and disabilities Monitoring, support and training in self-care Mental wellbeing through p sychological first aid and therapeutic counsellin g 4: Combat stigma and ensure human rights are respected Adoption of Principles and Guidelines for elimination of discrimination against persons affected by leprosy and their family members Inclusion of organisations and networks of persons affected by leprosy Amendment of discriminatory laws S ystems to monitor stigma reduction in communities Access to social support and rehabilitation Research The strategy includes a set of research priorities of key importance for this strategic period. Global and national investment in research are essential to achieving zero leprosy. OVERVIEW AND CONTEXT Leprosy is classified by WHO as one of twenty neglected tropical diseases (NTDs) 1 . Like other NTDs , its occurrence is often related to poor socio-economic conditions. It is a c ommunicable disease , caused by the bacillus Mycobacterium leprae 2 , with a long incubation period . Leprosy is l ikely transmitted by droplets from the nose and mouth during prolonged and close contact with untreated leprosy patients . It a ffects the skin and peripheral nerves and , if untreated, can progress to p ermanent impairments to the skin, nerves, face, hands and feet , and to disabilities and social exclusion. Stigma and discrimination have played a major role in leprosy for millennia: overcoming them is important to reach zero leprosy . Following the successful introduction of multidrug therapy in 1981, WHO strategies focused on reducing prevalence , initially to below 1:10,000 population, and then on further reducing new case detection, disability ( especially among children ) , and stigma and discrimination 3 . Some countries have achieved very low case numbers and may have interrupted community transmission. In recent years, a single dose of rifampicin as preventive chemotherapy has proven effective in reducing the risk of leprosy in contacts of leprosy patients 4 . These developments have encouraged WHO to reset the target for leprosy as elimination , defined as interruption of transmission 1 . During 2020 , WHO is developing standard operating procedures to verify elimination of transmission , in which a key element will be a commitment to post-elimination surveillance. Incorporating the goals of zero disability and zero discrimination, this strategy is boldly entitled Towards Zero Leprosy. The Global Leprosy Strategy 2021 ‒ 2030 is one of the disease-specific strategies underlying the WHO Road M ap for N eglected T ropical D iseases 2021–2030 . The leprosy profile from the Roadmap is attached as an Annex . The Roadmap , its companion documents and the related strategies are a significant contribution to the S ustainable D evelopment Goals (SD Gs ) , especially SDG 3 (healthy lives and wellbeing , including the goal of universal health coverage) , SDG 10 (reduce d inequalities) and SDG 17 (partnerships). The commitments of the SDGs are to leave no one behind and to endeavour to reach the furthest behind first 5 . Through the combination of disability and stigma, persons affected by leprosy are consistently among the most left behind. This strategy sets out to challenge and change that. The role of partners, at global and country level, is significant. The formation in 2018 of the Global Partnership for Zero Leprosy (GPZL) 6 has been a major step forward in aligning the efforts and priorities of partners and stakeholders throughout the leprosy world. Its leadership team includes representatives of national leprosy programmes, the private sector, nongovernmental organizations ( NGOs ), donors, academia, organisations of persons affected by leprosy, and WHO Global Leprosy Programme ( as observer ) . The emergence of networks of persons affected , supported in recent years by the U nited Nations Special Rapporteur on the elimination of discrimination against persons affected by leprosy and their family members , has given them greater confidence and a stronger voice 7 . Fundamental gaps in knowledge continue to impede progress. After a comprehensive review involving national programmes and scientists worldwide, GPZL and the Leprosy Research Initiative have developed a consensus set of research priorities 8 which the wider leprosy community is urged to support . This Global Leprosy Strategy 2021 ‒ 2030 present s the basic direction, goals, challenges and strategic pillars at a global level. National NTD and leprosy programmes in both high-incidence and low-incidence settings should adopt t he strategy and then adapt its targets and strategic pillars to the country context . ACHIEVEMENTS AND CURRENT SITUATION In four decades since the introduction of MDT, 20 million people have been cured and leprosy prevalence has reduced by 95%. In line with the W orld Health Assembly resolution in 1991 9 , global leprosy strategies focused initially on elimination of leprosy as a public health problem (defined as registered prevalence of less than 1 case per 10 000 population) , which was achieved at the global level in 2000. Subsequent five-year strategies focused on further reducing the disease burden through early detection and prompt treatment in the sustainable context of integrated services. By 2015, the target of elimination as a public health problem had been achieved in almost all countries, at least at national level. Factors underlying this achievement included political commitment, collaboration with major partners, and the free availability of MDT supplied by Novartis and distributed through WHO. But the very slight downward trend in new case numbers was showing the limitation s of a strategy reliant s olely on early case finding and treatment with MD T , and successive strategies had done little to reduce the physical, mental, social and economic consequences of leprosy on affected individuals and their families. The WHO 2016‒2020 Global Leprosy Strategy 3 sought to redefine disease burden in terms other than registered prevalence and the often misinterpreted ‘elimination as a public health problem’. N ew targets emphasi s ed a decrease in child cases and new cases with grade-2 disabilities, thereby promoting early detection and reduction of transmission, and reduction in the stigma and discrimination experienced by persons affected by leprosy and their families. Table 1 shows the progress made towards the 2020 targets in the strategy . TABLE 1 : PROGRESS TOWARDS 2020 GLOBAL TARGETS Impact indicator 2020 target 201 9 status Rate of grade-2 disabilities in newly detected cases < 1/million population 1. 4 /million population Newly detected child cases with grade-2 disability Zero Reported: 3 7 0 Estimated total: 400-500 Number of laws allowing discrimination on the basis of leprosy Zero countries with discriminatory laws 127 discriminatory laws in 22 countries 10 Leprosy data were reported by 160 countries in 201 9 1 1 . 202 185 new cases were detected in 11 6 countries ( 26.0 per million world population) . 96% of the new cases were in the 23 global priority countries 1 2 , including 79 % in India, Brazil and Indonesia. But, as Ta ble 2 shows, 6 4 countries were reporting fewer than 100 cases . TABLE 2 : REGIONAL DATA FOR 201 9 Region Countries reporting new cases New cases reported Rate/ 1 ,0 00,000 < 100 cases 100-1000 cases > 1000 cases Africa 38 20, 20 9 18 .0 13 18 7 Americas 24 29,936 29.5 16 7 1 Eastern Mediterranean 13 4,211 5.8 8 4 1 Europe 7 42 <0.1 7 0 0 South East Asia 10 143,787 70.4 2 2 6 Western Pacific 24 4, 004 2.1 18 5 1 Total 11 6 202,18 9 26.0 6 4 36 16 left top 10 813 new cases in 93 countries , including 370 c hildren, had grade-2 disability at the time of diagnosis, an indication of late diagnosis and lack of community awareness. The number of children is likely to be a significant ly higher understatement, as some countries do not report data on grade-2 disability in children. The overall grade-2 disability rate was 1. 4 per million population (down from 2.0 in 2014). 39 .6 % of the new cases were female, and 7 .4 % were children. Detection of cases in children is considered an indicator of recent transmission of infection in the community. Globally, the new case detection rate for those age d 0 to 14 years was 7. 9 per million children , down from 10. 1 in 2014. 47 countries reported treatment completion rates above 85%. 3 897 relapses were reported by 54 countries – 44 % of them in Brazil – up from 1175 in 2014. The increase may be attributed to better reporting though there are still weaknesses in diagnosing relapse. The relapse rate in leprosy appears low at around 1% over 5-10 years , and reports of drug resistance are rare. There is limited availability of second-line drugs for leprosy. In the absence of verifiable data, i t is estimated that 3-4 million people are living with visible impairments or deformities due to leprosy. Because both the ‘label’ of leprosy and the disability it causes result in social exclusion in many communities, the number of people experiencing leprosy-related stigma is likely to be even greater. There are ongoing efforts to reduce discrimination, including to repeal all discriminatory laws and regulations in force . 56 countries (3 5 %) reported the a vailability of counselling services, an important provision because of the known mental health consequences of leprosy diagnosis, stigma and social exclusion. In 2018, WHO published evidence-based Guidelines for the diagnosis, treatment and prevention of leprosy 1 3 . The document recommend s that national programmes adopt preventive treatment of contacts with single dose of rifampicin , and WHO has published technical guidance on contact tracing and preventive chemotherapy in 2020 1 4 . The Guidelines also address several areas of clinical uncertainty in the diagnosis, treatment and prevention of leprosy. In 2020, WHO published updated guidance on the management of leprosy reactions and neuritis 1 5 , and a guide for surveillance of antimicrobial resistance in leprosy 1 6 . Leprosy and other NTD programmes need to be managed within the new reality of pandemics like COVID-19. Alongside WHO guidance 1 7 on how to mitigate such situations, countries are advised to place more emphasis on telemedicine, tele-working (not only in clinical services but also in training, supervision and monitoring), and other creative approaches to protect staff and patients from risk. MAJOR CHALLENGES Delay in detection is evidenced by the relatively high proportion of new cases with grade-2 disability. Causes may include lack of capacity to diagnose , lack of a point-of-care diagnostic test to detect leprosy infection or disease 1 8 , weak case-finding and contact tracing program me s, lack of community awareness , and the stigma a ssociated with leprosy. Limited or dwindling capacity and leprosy expertise at all levels in the health workforce , including skills in program me management and monitoring and evaluation, are an issue in almost every endemic country, associated with loss of political attention and inadequate domestic funding. Inadequate laboratory services are also a risk. Meaningful engagement of relevant stakeholders is still limited. There is often political apathy and lack of a comprehensive approach between government ministries . Organi z ations of persons affected by leprosy , a vital stakeholder, are still in their infancy in many countries. Greater interaction is needed with private practitioners and traditional healers . Stigma and discrimination are deeply embedded in many communities , including healthcare settings, and result in exclusion and denial o f human rights . Conventional leprosy awareness program me s have proven insufficient to change community attitudes. Principles and guidelines for the elimination of discrimination 1 9 , adopted by the United Nations, are seldom incorporated into national policy frameworks. There remain significant research gaps . The consensus research agenda published in 2019 by GPZL 8 is a crucial contribution in terms of the evidence that needs to be generated towards the goal of zero leprosy. Ongoing interest and investment in research are essential. There is limited access or referral to essential care services for leprosy complications including reaction management, corrective surgery , assistive devices , wound care and self-care training, physical and socio-economic rehabilitation, and counselling and psychological first aid services . Routine s urveillance systems are yet to be put in place by most countries , either for sparse or hidden cases or for p ost-treatment monitoring of n erve damage and other disabling complications . Weak health information systems including paper-based systems at the periphery lead to poor data quality and gaps in recording and reporting of key information on which decisions should be based . Migration has meant that some countries with no autochthonous cases are reporting leprosy among foreign-born persons, with the potential risk of new leprosy transmission. L aboratories in several leprosy endemic countries monitor antimicrobial resistance (AMR) . Resistance to fi r st-line drugs appears low , but e xpansion of AMR monitoring is essential especially as post-exposure prophylaxis is scaled up. Adverse drug reactions include skin discolouration caused by clofazimine, and dapsone hypersensitivity. Pharmacovigilance systems should monitor adverse reactions to anti-leprosy drugs, reaction treatments, post-exposure prophylaxis and potential vaccines. Zoonotic transmission of M. leprae to humans by nine-banded armadillos ( Dasypus novemcinctus ) has been demonstrated 20 but until now the risk is low and highly locali z ed. VISION, GOAL, TARGETS AND PILLARS Long term v ision Zero leprosy : zero infection and disease, zero disability, zero stigma and discrimination right 140335 0 0 Goal Elimination of leprosy ( interruption of transmission ) 2 1 G lobal targets for 2030 120 countries reporting zero new autochthonous cases 70 % reduction * in annual number of new cases detected 90% reduction * in rate per million of new cases with grade-2 disability 90% reduction * in rate per million children of new child cases with leprosy * From 2020 baseline These are global targets. Countries will set targets relevant to their own leprosy situation and baseline data in order to contribute to the achievement of global targets . Strategic evaluations will be undertaken by WHO after 2023 and 2025 to assess progress and consider the need for course corrections or amended targets. Strategic pillars Implement integrated , country-owned zero leprosy roadmaps in all endemic countries Scale up leprosy preventi on alongside integrated active case detection Manage leprosy and its complications and prevent new disability Combat stigma and ensure human rights are respected Key research areas Table 3 lists research topics considered to be of key importance for this strategic period TABLE 3: KEY RESEARCH AREAS Diagnostic tests for disease and infection Improved understanding of transmission including host, agent and environmental factors and zoonotic transmission Improved understanding of the mechanism of leprosy reactions Optimised case detection through integration, especially in low-endemic settings More effective drugs or drug combinations , or shorter regimens, to treat leprosy and leprosy reactions Improved preventive approaches including chemotherapy regimen and vaccines Effective models of care throughout the patient journey Digital health applications in leprosy Inclusive approaches in community-based rehabilitation and stigma reduction Measuring progress and impact Table 4 shows the high-level impact indicators for leprosy in the NTD Roadmap 2021 ‒ 2030. Table 5 is a list of indicators to monitor progress and impact in implementing the strategic pillars. TABLE 4 : OVERALL IMPACT INDICATORS INDICATORS 2020 ( estimate ) 2023 2025 2030 Number of countries with zero new autochthonous cases 50 (26%) 75 (39%) 95 (49%) 120 (62%) N umber of new cases detected (disaggregated by sex and ag e ) 184, 000 14 8,000 123, 500 62,5 00 Rate (per million population) of new cases with grade-2 disability 1.30 0.92 0.68 0.12 Rate (per million children) of new child cases with leprosy 7.81 5.66 4.24 0.77 TABLE 5 : PROGRESS AND KEY INDICATORS FOR STRATEGIC PILLARS KEY ACTION INDICATORS PILLAR 1: Implement integrated , country-owned zero leprosy roadmaps in all endemic countries Political commitment Countries with established national partnerships for zero leprosy, incorporating government and partners including persons affected by leprosy Increasing share of leprosy budget financed by domestic sources Zero leprosy roadmaps Countries with multi-stakeholder z ero leprosy roadmaps in place Countries including persons affected by leprosy in planning of leprosy programmes Capacity building Strategy in operation to build and sustain leprosy capacity among health staff Surveillance and data management Effective surveillance system functioning Digital case-based data collection and reporting system in use Accurate records of patients with disabilities and/or at - risk as at the end of treatment AMR/ADR monitoring System in place to report relapses and to test for possible drug resistance Pharmacovigilance system in place to report on adverse drug reactions PILLAR 2: Scale up leprosy prevention alongside integrated active case detection Contact tracing Proportion of new cases for which contact tracing and screening applied Average number of contacts screened per index case Preventive chemotherapy Proportion of screened contacts who received preventive chemotherapy Active case-finding in targeted populations A ctive case-finding programmes in operation in relevant settings PILLAR 3: Manage leprosy and its complications and prevent new disability Early detection, diagnosis and treatment Proportion of new cases with grade-2 disability Number of new child cases with grade-2 disability Number of relapses Proportion of MB cases among new cases MDT completion rate Access to referral facilities Identified network of leprosy referral facilities available Management of reaction s, neuritis and disabilities Number of patients developing new disabilities during MDT treatment Proportion of patients having access to services for disease management Proportion of patients having access to assistive devices for disability prevention Self-care instruction Proportion of patients given self-care counselling Number of cured patients presenting with new disabilities after the end of treatment Mental wellbeing Availability of psychological first aid at all points of care Availability of therapeutic counselling and mental health referral services PILLAR 4: Combat stigma and ensure human rights are respected Adoption of Principles and Guidelines Absence of legislation allowing discrimination on the basis of leprosy Existence of positive norms or regulations facilitating social inclusion of persons affected by leprosy Inclusion of persons affected by leprosy Existence of national or regional associations of persons affected by leprosy for self-help and advocacy Stigma reduction Tools in use to assess social participation of persons affected by leprosy in the community Absence of r eports of exclusion of persons affected by leprosy or their family members fr om health facilities, schools or other public services on account of leprosy Social support and rehabilitation Access by persons affected by leprosy to social entitlements and community-based rehabilitation services STRATEGIC PILLAR 1 I mplement integrated , country -owned zero leprosy roadmaps in all endemic countries Key components Political commitment with adequate resources for leprosy in integrated context National partnerships for zero leprosy and zero leprosy roadmaps engaging all stakeholders Capacity building in the healthcare system for quality services Effective surveillance and improved data management systems Monitoring of antimicrobial resistance and adverse drug reactions Government ownership, partnerships, and national policies and strategies are critical factors for progress towards zero leprosy. H ealth, education, social development and law ministries may all share r esponsib ility for leprosy activities , so continuous ad vocacy and communication within and across m inistries are essential to increase engagement . Cross-border collaboration may be needed to ensure continuity of care and the interruption of transmission. Attaining all SDGs and NTD goals is founded on strong partnerships, so governments need to work in conjunction with WHO, academic institutions, the private sector, local and international NGOs , and C S Os including o rganisations of persons affected by leprosy . Coordination mechanisms such as national partnerships for zero leprosy should be established , i ncorporating relevant government and partner stakeholders including persons affected by leprosy . Such structures will ensure ongoing focus on leprosy when it is mainstreamed into national health systems and integrated with other health conditions , such as skin NTDs and NTDs associated with ongoing disease management and disability . Partners and academia should collaborate on basic and operational research to build the evidence base for better policies, strategies and programmes. Z ero leprosy roadmaps , integrated into national healthcare strategies, operate as a focus for the action of all stakeholders, in higher- and lower-endemic countries. They should be developed within a thorough , well-structured , country-led process supported by WHO and GPZL. The process involves a c ountry review to identify gaps and pri ori ties , development of a roadmap containing the steps and appropriate strategies and tools to reach zero leprosy in integrated contexts , and a monitoring and evaluation framework to enable progress to be measured. Leprosy, like other NTDs, must be included in budgets for domestic funding, sometimes supplemented through contributions by partners. Because leprosy incidence is not uniform across all subnational areas, roadmaps should incorporate a variety of strategic approaches relevant to sectors of the country with high, medium and low incidence. Staff capacity is, for many countries, the severest obstacle to achieving zero leprosy. Strategies are needed to build and sustain the capacity of integrated public health and clinical services staff in all aspects of leprosy prevention, screening, diagnosis, treatment and programme management. Innovative , e-health approaches should be considered for training and capacity-building . O rganisations of persons affected by leprosy , if involved as partners, may encourage early identification of leprosy and improve treatment adherence. L aboratory capacity , including capability for slit- skin smear s , needs to be maintained to support clinical diagnosis . Routine surveillance systems need to be put in place in all countries to detect hidden case s and endemic clusters, or to monitor nerve damage , physical impairments and mental health issues during and after trea tment. Effective data managemen t, based on digital case-based health information systems including geolocation data, is essential to accurately record and report progress towards zero leprosy and enable sound, evidence-based programmatic decisions. In line with WHO recommendations 1 6 , antimicrobial resistance should be monitored with the collaboration of expert laboratories in-country or elsewhere. Integrated with other p harmacovigilance systems, data should be collected and reported on adverse reactions to drugs used in leprosy prevention, treatment and reaction management, as well as potential vaccines. STRATEGIC PILLAR 2 Scale up leprosy prevention alongside integrated active case detection Key components Contact tracing for all new cases P reventive chemotherapy scaled up Integrated a ctive case-finding in targeted populations Existing and potential new vaccines Passive case detection and treatment with MDT alone have proven in sufficient to interrupt transmission . To boost the prevention of leprosy, w ith the consent of the index case , WHO recommend s tracing household contacts along with 25-50 neighbours and social contacts of each patient, accompanied by the offer of a single dose of rifampicin as preventive chemotherapy 1 4 . Ongoing research may produce a more effective regimen during the period of the strategy. Up to five years’ retrospective contact tracing will boost opportunities for case fi nding and prevention . D efined populations ( such as islands, institutions, urban slums, villages or even districts) with known high transmission may benefit from ‘blanket’ preventive chemotherapy . Alongside its role in the prevention of leprosy, c ontact tracing is considered the most productive tool for finding new cases . In addition, a ctive case-finding campaigns should be implemented in targeted populations such as areas of higher endemicity or among at-risk groups , ideally integrated with other skin NTDs or other relevant diseases. Case-finding campaigns should be accompanied by innovative and well-targeted community information and awareness activities that encourage early self-referral and positive attitudes towards persons affected by leprosy. Special attention should be given to ensuring that information and programmes are reaching women and girls, who may have reduced access to diagnosis and treatment due to cultural and other barriers. D ata should be disaggregated by gender to verify this . Countries reporting fewer than 100 new cases per year, and countries with low-incidence areas, need effective surveillance system s to respond to and investigate every new case . Contact screening, with the offer of preventive chemotherapy, should be routinely undertaken in these settings, and active case-finding may be considered in any clusters. These measures will enable low-incidence countries and areas to achieve and sustain the goal of zero transmission. WHO recommends BCG vaccin ation at birth as an effective tool for reducing the risk of lepros y. Its use should be maintained , at least in co untries or setting s with a high leprosy burden. Repeat BCG vaccinations for leprosy are not recommended 2 2 . Trials of other existing and potential new vaccines, including LepVax which is in human trials in 2020, may result in a significant new tool for leprosy prevention during this strategy period. STRATEGIC PILLAR 3 Manage leprosy and its complications and p revent new disability Key components Early case detection, accurate diagnosis and prompt treatment with MDT Access to comprehensive, well-organised referral facilities Diagnosis and management of leprosy reactions , neuritis and disabilities Monitoring, support and training in self-care Mental wellbeing through p sychological first aid and therapeutic counsellin g Early case detection and prompt treatment with 6-12 months’ MDT (dapsone, clofazimine and rifampicin) continue to be the mainstay of effective leprosy control. Countries have varying approaches to the integration of leprosy into healthcare systems . WHO recommends integrated skin NTD strategies where feasible 2 3 , with active coordination in all relevant aspects of planning, management, programme implementation and monitoring and evaluation . In line with UHC goals, m apping tools should be used, and surveillance systems developed , to ensure detection of sporadic and hidden cases and monitor progress. Leprosy programme managers should engage with private practitioners and with traditional healers. Close attention is needed to the supply chain for MDT, prophylactic drugs, second - line drugs and drugs to treat leprosy reactions – especially last-mile delivery. During MDT treatment, a significant proportion of patients experience complications such as leprosy reactions and nerve damage leading to new grade - 1 (loss of sensation) and /or grade - 2 disability (visible impairments ). W ell-organised referral systems should provide access to suitably resourced health facilities that can manage reactions , offer wound care , deal with other complications such as damage to the eye , supply assistive devices such as tailor-made footwear along with training and advice on self-care, and offer reconstructive surgery with associated physiotherapy services . Health staff need training in nerve function assessment and to recogni s e and treat or promptly refer signs and symptoms of leprosy reactions and neuritis. Careful attention should be given to ensuring equitable access to services by women and girls and, where necessary, supporting the costs of travel to the referral centre . M ajor events that may occur after completion of treatment include leprosy reaction, recurrence of disease (relapse) and worsening of disabilities or occurrence of new disabilities. Although r elapse is relatively rare, laboratory facilities are needed to confirm it and track relapse trends. R eactions, worsening of disabilities and new disabilities (particularly grade - 1 progressing to grade - 2) are relatively common , and negatively affect the quality of life of persons affected by leprosy . Thorough examinations including nerve function assessments and EHF (eye-hand-foot) scores should be undertaken at the beginning and end of M DT treatment, followed by post-treatment s urveillance , to identi f y, record, monitor and provide customised support for persons who at high er risk of developing reactions or worsening disability and need ongoing care . Ideally, prevention of disabilities should start with maintaining grade-0 (no disability) status by early diagnosis and treatment of leprosy reaction s and neuritis. Nerve function impairment ( grade-1 ) often manifests in eyes, hands and feet which are most used in daily activities of life and are prone to injuries and ulcer formations . These, if neglected , lead to infection, tissue loss and disfiguration. Patients and former patients at risk need training on disability prevention and self-care to prevent injuries and protect limbs and eyes. These interventions may be integrated with similar services for other disabling NTDs. Access to clean water is important for routine self - care including daily soaking of hands and feet to prevent secondary disabilities . Psychological first aid 2 4 should be available at all points of care , supported by referral to therapeutic counselling and other services promoting mental wellbeing. These services play a crucial role in enabling persons affected by leprosy and their family and community members to better understand the diagnosis and its impact, cope with stigma related events and provide a supportive environment . STRATEGIC PILLAR 4 Combat stigma and ensure human rights are respected Key components Adoption of Principles and Guidelines for elimination of discrimination against persons affected by leprosy and their family members Inclusion of organisations and networks of persons affected by leprosy Amendment of discriminatory laws S ystems to monitor stigma reduction in communities Access to social support and rehabilitation Stigma and discrimination against persons affected by leprosy and their families are almost as old as recorded history . Effects may include social exclusion, loss of income, reduced access to healthcare and education, and reduced mental wellbeing. Changing beliefs and prejudices is not easy, though school children may be more receptive than adults to messages about changing behaviour and attitudes. Reduction in community stigma promotes early detection and improves acceptance of diagnosis and adherence to treatment and self-care practices. The Principles and Guidelines for elimination of discrimination against persons affected by leprosy and their family members 1 9 were adopted by the United Nations General Assembly in 201 1. They largely echo the UN Convention on the Rights of Persons with Disabilitie s, which has been ratified by most countries . The Principles and Guidelines , attached as an Annex to this strategy, should be adopted and enacted by governments within the framework of the country’s existing human rights systems , so as to protect the rights of persons affected by leprosy and to stimulate actions , particularly at community level, that combat stigma a nd discrimination. These actions should include initiatives to improve the knowledge and attitudes towards leprosy of people employed in healthcare, education and social services , and among community and religious leaders . There should be zero cases of persons affected by leprosy or their family members being excluded from health facilities, schools or other public services on account of leprosy . Persons affected by leprosy should be encouraged and supported to form self-help groups , ideally including other persons with disabilities or facing social exclusion, for mutual support , advocacy and the development of livelihoods and socioeconomic advancement. Initiatives should be taken to s trengthen the capacity of community-based organisations and networks of persons affected by leprosy so that they can provide meaningful engagement on issues relevant to them at all decision-making levels 2 5 ,2 6 . L aws and regulations allowing discrimination against persons affected by leprosy should be repeal ed or amend ed without delay and replaced with positive regulations that facilitate the inclusion of persons affected in the community . Countries should use the available tools to collect data on the level of social exclusion in selected communities , and monitor over time to assess the impact of stigma reduction strategies which may be focused not only on leprosy but also on other stigmatised NTDs. Special attention should be given to vulnerable populations including women, children, immigrants, refugees, the elderly, the homeless, and those living in geographically inaccessible areas. An estimated 3-4 million people live with physical disabilities caused by leprosy, and potentially a greater number suffer stigmatisation and social exclusion. The social, mental and economic impacts of leprosy are arguably a greater burden than the disease itself. Persons affected by leprosy need access to mainstreamed community-based rehabilitation services focused on mitigating the effect of impairments and optimising inclusion in the community 2 7 . Access to the country’s framework of social entitlements and other welfare measures is also essential to reduce adverse socio-economic consequences . ENDNOTES AND REFERENCES Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. Geneva: World Health Organization , 2020 Mycobacterium lepromatosis , a genetically similar organism to M. leprae , is also an established cause Global Leprosy Strategy 2016 ‒ 2020: Accelerating towards a leprosy-free world. Regional Office for South-East Asia: World Health Organization, 2016. https://apps.who.int/iris/handle/10665/208824 Moet FJ, Pahan D, Oskam L, Richardus JH. 2008. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ 336: 761–764. Transforming our world: the 2030 agenda for sustainable development. New York: United Nations, 2015. https://sustainabledevelopment.un.org/post2015/transformingourworld/publication Global Partnership for Zero Leprosy. https://zeroleprosy.org/ Summary, Conclusions and Recommendations - Global Forum of People's Organizations on Hansen ’s Disease in Manila, 7-10 September 2019 . https://www.shf.or.jp/information/6813?lang=en Global Partnership for Zero Leprosy: GPZL Reports on Research Priorities; Leprosy Review; 2019; 90; 3; 237-289 World Health Assembly Resolution WHA44.9. Hbk Res., Vol. III (2nd ed.), 1.16.8, World Health Assembly, 1991. https://www.who.int/neglected_diseases/mediacentre/WHA_44.9_Eng.pdf The global leprosy update for 2019 report s 111 discriminatory laws from 6 countries , exclud ing regulations and customary practices . The global legislation database maintained by ILEP enumerates 13 0 discriminatory laws and regulations in 23 countries as at September 2020. https://ilepfederation.org/ Global leprosy (Hansen disease) update, 201 9 : time to step-up prevention activities . Weekly Epidemiological Record, vol. 9 5 (36) 417-440 . https://apps.who.int/iris/handle/10665/334141 Global priority countries were initially derived in 2016 from a composite index using parameters such as prevalence, new case detection, proportions of female child and G2D cases. The countries are Angola, Bangladesh, Brazil, Comoros, Côte d’Ivoire, Democratic Republic of the Congo, Egypt, Ethiopia, Federated States of Micronesia, India, Indonesia, Kiribati, Madagascar, Mozambique, Myanmar, Nepal, Nigeria, Philippines, South Sudan, Sri Lanka, Sudan, Somalia (added in 2018), United Republic of Tanzania. Guidelines for the diagnosis, treatment and prevention of leprosy. Regional Office for South-East Asia: World Health Organization, 2018. https://apps.who.int/iris/handle/10665/274127 Leprosy/Hansen disease: contact tracing and post-exposure prophylaxis: Technical guidance . Regional Office for South-East Asia : World Health Organization, 2020. Add URL when available Leprosy/Hansen Disease: Management of reactions and prevention of disabilities. Regional Office for South-East Asia : World Health Organization, 2020. https://apps.who.int/iris/handle/10665/332022 A guide for surveillance of antimicrobial resistance in leprosy : 2017 update. Regional Office for South-East Asia: World Health Organization, 2017 . https://apps.who.int/iris/handle/10665/259357 Considerations for implementing mass treatment, active case‐finding and population-based surveys for neglected tropical diseases in the context of the COVID-19 pandemic: interim guidance. Geneva: World Health Organization, 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-neglected-tropical-diseases-2020-1 In 2019, the newly formed WHO Diagnostic Technical Expert Group for NTDs classified leprosy as high priority for diagnostics development, listing the need for point of care diagnosis of infection, screening for potential disease, diagnosis of disease, prediction of future disease, and diagnosis of nerve function loss. Source: Report of the first meeting of the WHO Diagnostic Technical Advisory Group for Neglected Tropical Diseases Geneva, Switzerland, 30–31 October 2019 . Geneva: World Health Organization, 2020. https://apps.who.int/iris/handle/10665/331954 Resolution adopted by the General Assembly on the report of the Third Committee (A/65/456/ Add.2 (Part II)). Elimination of discrimination against persons affected by leprosy and their family members; Principles and guidelines for the elimination of discrimination against persons affected by leprosy and their family members. New York: United Nations, 2011. https://ilepfederation.org/wp-content/uploads/2020/02/ILEP-Principles-Guidelines.pdf . Refer also Annex 2 Sharma R , Singh P , Loughry WJ et al. 2015. Zoonotic Leprosy in the southeastern United States. Emerg Infect Dis 21: 2127–2134. Elimination is defined as reduction to zero of the incidence of leprosy infection in a defined geographical area, with ongoing surveillance to detect and prevent re-establishment of transmission. BCG vaccines: WHO position paper - February 2018. Weekly Epidemiological Record, 23 February 2018, vol. 93 (pp. 73-96). https://apps.who.int/iris/handle/10665/260306 Recognizing neglected tropical diseases through changes on the skin: a training guide for front-line health workers. Geneva: World Health Organization, 2018. https://apps.who.int/iris/handle/10665/272723 Psychological first aid: guide for field workers. Geneva: World Health Organization, War Trauma Foundation & World Vision International, 2011. https://apps.who.int/iris/handle/10665/44615 Guidelines for strengthening participation of persons affected by leprosy in leprosy services. Regional Office for South-East Asia: World Health Organization, 2011. https://apps.who.int/iris/bitstream/handle/10665/205169/B4726.pdf?sequence=1&isAllowed=y Report of the informal consultation on stopping discrimination and promoting inclusion of persons affected by leprosy: New Delhi 14-16 November 2017. Regional Office for South-East Asia : World Health Organization, 2018. https://apps.who.int/iris/handle/10665/272637 WHO/ILEP technical guide on community-based rehabilitation and leprosy: meeting the rehabilitation needs of people affected by leprosy and promoting quality of life . Geneva: World Health Organization, International Federation of Anti-Leprosy Associations, 2007. https://apps.who.int/iris/handle/10665/43748 ANNEX 1 : Leprosy profile from WHO NTD Roadmap 2021 ‒ 2030 ANNEX 2 : Principles and guidelines for the elimination of discrimination against persons affected by leprosy and their family members I. Principles Persons affected by leprosy and their family members should be treated as people with dignity and are entitled, on an equal basis with others, to all the human rights and fundamental freedoms proclaimed in the Universal Declaration of Human Rights, as well as in other relevant international human rights instruments to which their respective States are parties, including the International Covenant on Economic, Social and Cultural Rights, the International Covenant on Civil and Political Rights, and the Convention on the Rights of Persons with Disabilities. Persons affected by leprosy and their family members should not be discriminated against on the grounds of having or having had leprosy. Persons affected by leprosy and their family members should have the same rights as everyone else with respect to marriage, family and parenthood. To this end: No one should be denied the right to marry on the grounds of leprosy Leprosy should not constitute a ground for divorce A child should not be separated from his or her parents on the grounds of leprosy. Persons affected by leprosy and their family members should have the same rights as everyone else in relation to full citizenship and obtaining identity documents. Persons affected by leprosy and their family members should have the right to serve the public, on an equal basis with others, including the right to stand for elections and to hold office at all levels of government. Persons affected by leprosy and their family members should have the right to work in an environment that is inclusive and to be treated on an equal basis with others in all policies and processes related to recruitment, hiring, promotion, salary, continuance of employment and career advancement. Persons affected by leprosy and their family members should not be denied admission to or be expelled from schools or training programmes on the grounds of leprosy. Persons affected by leprosy and their family members are entitled to develop their human potential to the fullest extent , and to fully realize their dignity and self-worth. Persons affected by leprosy and their family members who have been empowered and who have had the opportunity to develop their abilities can be powerful agents of social change. Persons affected by leprosy and their family members have the right to be, and should be, actively involved in decision-making processes regarding policies and programmes that directly concern their lives. II. Guidelines 1. General States should promote, protect and ensure the full realization of all human rights and fundamental freedoms for all persons affected by leprosy and their family members without discrimination on the grounds of leprosy. To this end, States should: Take all appropriate legislative, administrative and other measures to modify, repeal or abolish existing laws, regulations, policies, customs and practices that discriminate directly or indirectly against persons affected by leprosy and their family members, or that forcefully or compulsorily segregate and isolate persons on the grounds of leprosy in the context of such discrimination Ensure that all authorities and institutions take measures to eliminate discrimination on the grounds of leprosy by any person, organization or private enterprise. States should take all appropriate measures to achieve for persons affected by leprosy and their family members the full realization of all the rights enshrined in the Universal Declaration of Human Rights and the international human rights instruments to which they are party, including the International Covenant on Economic, Social and Cultural Rights, the International Covenant on Civil and Political Rights and the Convention on the Rights of Persons with Disabilities. In the development and implementation of legislation and policies and in other decision-making processes concerning issues relating to persons affected by leprosy and their family members, States should consult closely with and actively involve persons affected by leprosy and their family members, individually or through their respective local and national organizations. 2. Equality and non-discrimination States should recognize that all persons are equal before and under the law and are entitled, without any discrimination, to the equal protection and equal benefit of the law. States should prohibit all discrimination on the grounds of a person having or having had leprosy, and should guarantee equal and effective legal protection to persons affected by leprosy and their family members. Specific measures which are necessary to achieve de facto equality of persons affected by leprosy and their family members shall not be considered as discrimination. 3. Women, children and other vulnerable groups In many societies, leprosy has a significantly adverse impact on women, children and other vulnerable groups. States should therefore pay special attention to the promotion and protection of the human rights of women, children and members of other vulnerable groups who have or have had leprosy, as well as their family members. States should promote the full development, advancement and empowerment of women, children and members of other vulnerable groups who have or have had leprosy, as well as their family members. 4. Home and family States should, where possible, support the reunification of families separated in the past as a result of policies and practices relating to persons diagnosed with leprosy. 5. Living in the community and housing States should promote the enjoyment of the same rights for persons affected by leprosy and their family members as for everyone else, allowing their full inclusion and participation in the community. States should identify persons affected by leprosy and their family members living in isolation or segregated from their community because of their disease, and should give them social support. States should enable persons affected by leprosy and their family members to choose their place of residence and should ensure that they are not obliged to accept a particular living arrangement because of their disease. States should allow any persons affected by leprosy and their family members who were once forcibly isolated by State policies in effect at the time to continue to live in the leprosariums and hospitals that have become their homes, if they so desire. In the event that relocation is unavoidable, the residents of these places should be active participants in decisions concerning their future. States should, however, improve living conditions in those leprosariums and hospitals. With due regard to the wishes of the persons affected by leprosy and their family members, and with their full participation, States should also design, promote and implement plans for the gradual integration of the residents of such places in the community and for the gradual phasing out of such leprosariums and hospitals. 6. Participation in political life States should ensure that persons affected by leprosy, and their family members, enjoy voting rights, the right to stand for election and the right to hold public office at all levels of government, on an equal basis with others. Voting procedures must be accessible, easy to use and adapted to accommodate any individuals physically affected by leprosy. 7. Occupation States should encourage and support opportunities for self-employment, the formation of cooperatives and vocational training for persons affected by leprosy and their family members, as well as their employment in regular labour markets. 8. Education States should promote equal access to education for persons affected by leprosy and their family members. 9. Discriminatory language States should remove discriminatory language, including the derogatory use of the term “leper” or its equivalent in any language or dialect, from governmental publications and should revise expeditiously, where possible, existing publications containing such language. 10. Participation in public, cultural and recreational activities States should promote the equal enjoyment of the rights and freedoms of persons affected by leprosy and their family members, as enshrined in the Universal Declaration of Human Rights and the international human rights instruments to which they are party, including, the International Covenant on Economic, Social and Cultural Rights, the International Covenant on Civil and Political Rights and the Convention on the Rights of Persons with Disabilities. States should promote access on an equal basis with others to public places, including hotels, restaurants and buses, trains and other forms of public transport for persons affected by leprosy and their family members. States should promote access on an equal basis with others to cultural and recreational facilities for persons affected by leprosy and their family members. States should promote access on an equal basis with others to places of worship for persons affected by leprosy and their family members. 11. Health care States should provide persons affected by leprosy at least with the same range, quality and standard of free or affordable health care as that provided for persons with other diseases. In addition, States should provide for early detection programmes and ensure prompt treatment of leprosy, including treatment for any reactions and nerve damage that may occur, in order to prevent the development of stigmatic consequences. States should include psychological and social counselling as standard care offered to persons affected by leprosy who are undergoing diagnosis and treatment, and as needed after the completion of treatment. States should ensure that persons affected by leprosy have access to free medication for leprosy, as well as appropriate health care. 12. Standard of living States should recognize the right of persons affected by leprosy and their family members to an adequate standard of living, and should take appropriate steps to safeguard and promote that right, without discrimination on the grounds of leprosy, with regard to food, clothing, housing, drinking water, sewage systems and other living conditions. States should: Promote collaborative programmes involving the Government, civil society and private institutions to raise funds and develop programmes to improve the standard of living Provide or ensure the provision of education to children whose families are living in poverty by means of scholarships and other programmes sponsored by the Government and/or civil society Ensure that persons living in poverty have access to vocational training programmes, microcredit and other means to improve their standard of living. States should promote the realization of this right through financial measures, such as the following: Persons affected by leprosy and their family members who are not able to work because of their age, illness or disability should be provided with a government pension Persons affected by leprosy and their family members who are living in poverty should be provided with financial assistance for housing and health care. 13. Awareness-raising States, working with human rights institutions, non-governmental organizations, civil society and the media, should formulate policies and plans of action to raise awareness throughout society and to foster respect for the rights and dignity of persons affected by leprosy and their family members. These policies and plans of action may include the following goals: To provide information about leprosy at all levels of the education system, beginning with early childhood education affirming, inter alia, that leprosy is curable and should not be used as grounds for discrimination against persons who have or have had leprosy and their families To promote the production and dissemination of “know your rights” material to give to all persons recently diagnosed with leprosy To encourage the media to portray persons affected by leprosy and their family members with dignified images and terminology To recognize the skills, merits and abilities of persons affected by leprosy and their contribution to society and, where possible, to support exhibitions of their artistic, cultural and scientific talents To encourage creative persons, including artists, poets, musicians and writers, particularly those who have personally faced the challenges of leprosy, to make a contribution to awareness-raising through their specific talents To provide information to social leaders, including religious leaders, on how addressing leprosy in their teachings or written materials may contribute to the elimination of discrimination against persons affected by the disease and their family members To encourage higher education institutions, including medical schools and nursing schools, to include information about leprosy in their curricula, and to develop and implement a “train the trainer” programme and targeted educational materials To promote implementation of the World Programme for Human Rights Education and to incorporate the human rights of persons affected by leprosy and their family members into the national human rights education programme of each State To identify ways to recognize, honour and learn from the lives of individuals forcibly isolated by their Governments for having been diagnosed with leprosy, including oral history programmes, museums, monuments and publications To support grass-roots awareness efforts to reach communities without access to traditional media. 14. Development, implementation and follow-up to States’ activities States should consider creating or designating a committee to address activities relating to the human rights of persons affected by leprosy and their family members. The committee should ideally include individuals affected by leprosy and their family members, representatives of organizations of persons affected by leprosy, human rights experts, representatives from the human rights field and related fields, and representatives of government. States are encouraged to include in their State party reports to the relevant treaty bodies the policies and measures that they have adopted and/or implemented with regard to the elimination of discrimination against persons affected by leprosy and their family members.